The investors in ImmunityBio, Inc. 's ( NASDAQ:IBRX ) will be rubbing their hands together with glee today, after ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...

ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a ...

ImmunityBio, Inc.’s IBRX share price has surged by 10.14%, which has investors questioning if this is right time to sell.

ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago. These figures are ...

ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA ...

Shares of ImmunityBio Inc. grew as much as 18.8 percent at intraday trading before ending the day just up by 14.01 percent at ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $129.6 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of 15 ...

CULVER CITY, Calif., May 12, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028 ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $129.6 million in its first quarter. On a per-share basis, the San Diego-based company said it had a ...